On December 14, Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. announced that the FDA has approved trastuzumab-pkrb (Herzuma), a biosimilar to Herceptin, for the treatment of HER2-positive breast cancer.
Read the Celltrion press release here.
Posted 12/17/2018
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
